Lower Your Cholesterol, Protect Your Heart

Risk-stratified therapy with LDL, non-HDL, and ApoB targets for Indian patients

Book High Cholesterol Consultation

30–55%

LDL Reduction

Typical on moderate–high intensity statins ± ezetimibe

2–4 weeks

First Review

Dose check, side-effect screen, and adherence coaching

70%

Triglyceride Control

Patients reach <150 mg/dL with combined plan

When to Consult

•LDL ≥190 mg/dL or non-HDL ≥220 mg/dL on any routine test
•Triglycerides ≥200 mg/dL, especially with diabetes or fatty liver
•Family history of early heart disease or known familial hypercholesterolemia
•Chest pain, breathlessness on exertion, or abnormal ECG during check-ups
•Xanthelasma, tendon xanthomas, or fatty liver on ultrasound with high lipids
•You stopped statins due to aches or worry and want a safe re-trial plan

Understanding High Cholesterol in the Indian Context

Indians develop heart disease at younger ages with smaller waist gains. Focusing on LDL, non-HDL, and ApoB helps tailor therapy to mixed diets and sedentary work patterns common in Hyderabad.

When to Consult Our Lipid Specialists

⚠️ Seek urgent care for:

✓ Chest pain or severe breathlessness
✓ Fainting, new weakness, or slurred speech
✓ Triglycerides >500 mg/dL with abdominal pain (pancreatitis risk)

Book a routine visit if your LDL is high, triglycerides are elevated, or you have family history of early heart disease.

Our Diagnostic Approach

Lipid Profile and Non-HDL Targets

We calculate non-HDL (total cholesterol − HDL) alongside LDL to capture all atherogenic particles.

Screen for Secondary Causes

We check thyroid, liver, kidney function, diabetes control, alcohol intake, and medication contributors.

Risk Stratification

We set targets by ASCVD risk and prevention category suitable for Indian patients.

Advanced Markers (Selective)

ApoB, lipoprotein(a), and CT calcium score guide decisions when standard tests are inconclusive.

Treatment Pathways

From diet and activity to statins, ezetimibe, omega-3/fibrate for high TG, and an FH clinic when inherited risk is suspected, we individualise plans with tele follow-ups to maintain progress.

What to Expect: Your Care Journey

Week 0 baseline and plan → Week 2–4 tolerance and dose check → Week 6–8 target review → Months 3–6 consolidation → Quarterly maintenance.

Technology & Innovation

ApoB/non-HDL dashboards and EMR-linked reminders support timely dose adjustments and fewer visits.

Preventing Complications

Meeting lipid targets reduces heart attack, stroke, and pancreatitis (when TG is very high). Early action is key.

Why Ajuda for Lipid Care?

📊 Target-Driven Plans

LDL and non-HDL goals matched to your personal risk.

🥗 Practical Diet Coaching

Millets-forward menus, festival strategies, and easy kitchen swaps.

📱 Tele Follow-ups

WhatsApp check-ins keep you consistent and side-effect free.

Take the First Step

Call 9010550550 or book online for a lipid review and a personalised plan that fits your life.

Diagnosis Approach

Comprehensive Lipid Profile

LDL-C, HDL-C, triglycerides, non-HDL-C; non-fasting acceptable in many, fasting if TG is high.

Secondary Causes Screen

TSH, LFTs, renal function, diabetes control, alcohol, hypothyroidism, and medications that raise lipids.

Risk Stratification

ASCVD risk estimation with Indian context; set LDL/non-HDL targets for primary vs secondary prevention.

Advanced Markers When Indicated

ApoB for atherogenic burden; consider lipoprotein(a) and CT calcium scoring in select patients.

Treatment Options

Lifestyle Program

Millets-forward, fibre-rich Indian plates, low-trans-fat cooking, portion control, and progressive walking + resistance training.

LDL ↓ 10–15%, TG ↓ 15–25% with adherence

12 weeks core; quarterly maintenance

Statin Therapy

Moderate–high intensity statin chosen to match risk and tolerance; vitamin D and interaction review to reduce myalgia.

LDL ↓ 30–50% typical

Ongoing with 4–12 week titration

Ezetimibe Add-on

Add when LDL above target despite statin or intolerance to higher doses.

Extra 15–25% LDL reduction

Ongoing; periodic lipid checks

Triglyceride Pathway

Address carbs/alcohol first; add omega-3/fibrate selectively, especially if TG ≥500 mg/dL to cut pancreatitis risk.

TG ↓ 20–50% depending on baseline

8–12 weeks then review

Familial Hypercholesterolemia (FH) Clinic

Cascade screening, aggressive targets, and advanced agents where available; cardiology co-management.

Early control reduces premature ASCVD events

Long-term follow-up

Tele Follow-ups

WhatsApp nudges, side-effect triage, and report review; dose tweaks without extra visits.

Improves adherence by ~25–30%

First 3 months intensive, then quarterly

Expected Outcomes

Treatment Timeline

2–4 Weeks

Tolerance check; early LDL/TG response visible

6–8 Weeks

Dose optimisation; most reach non-HDL targets

3–6 Months

Stable control; lifestyle habits established

1 Year+

Sustained targets; periodic risk re-assessment

Success Metrics

LDL at target for risk category
Triglycerides <150 mg/dL for most patients
Improved ASCVD risk score and stamina

Take Control of High Cholesterol Today

Emergency

9010550550

contact@ajudahospitals.in

Related Services

Hypertension Management

Shared cardiovascular risk reduction

Diabetes Management

Metabolic control improves lipid targets